|
[1] 秦奎.我国心脑血管疾病监测现状与发展[J].应用预防医学,2020,26(3):265-268.
[2] Asanin M, Stankovic S, Mrdovic I, et al.
B-type natriuretic peptide predicts new-onset atrial fibrillation in patients
with ST-segment elevation myocardial infarction treated by primary percutaneous
coronary intervention [J]. Peptides, 2012, 35(1): 74-77. DOI:
10.1016/j.peptides. 2012. 02.022.
[3] 吴蓝津,吴万芬,陆山河.NT-proBNP在心力衰竭中应用的研究进展[J].心血管康复医学杂志,2018,27(1):114-117.
DOI:10.3969/j.issn.1008-0074.2018.01.32.
[4] 杜坤,张梦情,邓琳,等.心力衰竭患者血清NT-proBN P和sST2水平变化及临床意义[J].国际检验医学杂志,2019,40(1):43-47. DOI:10.3969/j.issn.1673-4130.2019.01.012.
[5] 王华,柴坷,杨杰孚.2021年心力衰竭诊治进展[J].中国心血管病研究,2021,19(12):1067-1071. DOI:10.3969/j.issn.1672-5301.2021.12.03.
[6] 中华医学会心血管病学分会心力衰竭学组,中国医师协会心力衰竭专业委员会,中华心血管病杂志编辑委员会.中国心力衰竭诊断和治疗指南2018[J].中华心血管病杂志,2018,46(10):760-789.
DOI:10.3760/cma.j.issn.0253- 3758. 2018.10.004.
[7] Ponikowski P, Voors AA, Anker SD, et al.
2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart
failure: The Task Force for the diagnosis and treatment of acute and chronic
heart failure of the European Society of Cardiology (ESC). Developed with the
special contribution of the Heart Failure Association (HFA) of the ESC [J]. Eur
J Heart Fail, 2016,18(8):891-975. DOI: 10.1002/ejhf.592.
[8] Cao Z, Jia Y, Zhu B. BNP and NT-proBNP
as diagnostic biomarkers for cardiac dysfunction in both clinical and forensic
medicine [J]. Int J Mol Sci, 2019, 20(8):1820. DOI: 10.3390/ijms20081820.
[9] 李春兰,贺延平,何瑾.新型生物标记物在心力衰竭患者中的研究进展[J].中国心血管病研究,2021,19(12):1095-1098. DOI:10.3969/j.issn.1672-5301.2021.12.08.
[10] Charmetant X, Pecquet M, Poirié P, et
al. Impact of age and renal function on usefulness of NT-proBNP to diagnose
heart failure [J]. Clin Nephrol, 2019, 92(2):65-72. DOI: 10.5414/CN109480.
[11] 吕海珍,吕云,周荣,等.血清HCY、sST2和NT-proBNP联合检测对慢性心力衰竭诊断及心功能评价的价值[J].中国实验诊断学,2019,23(6):1002-1006.
DOI:10.3969/j.issn.1007-4287.2019.06.021.
[12] 徐亮,杨松,王稳,等.NT-proBNP对慢性心力衰竭患者心功能的评估价值[J].临床和实验医学杂志,2018,17(24):2626-2629.
DOI:10.3969/j.issn.1671-4695.2018.24.015.
[13] 杨鸿媚,安广隶,孙娜.NT-proBNP、LVEF在老年慢性充血性心力衰竭评估中的作用[J].解放军医药杂志,2019,31(2):46-49.
DOI:10.3969/j.issn.2095-140X.2019.02.011.
[14] Salah K, Stienen S, Pinto YM, et al.
Prognosis and NT-proBNP in heart failure patients with preserved versus reduced
ejection fraction [J]. Heart, 2019, 105(15):1182-1189. DOI: 10.1136/heartjnl-2018-314173.
[15] McCallum W, Tighiouart H, Kiernan MS, et
al. Relation of kidney function decline and NT-proBNP with risk of mortality
and readmission in acute decompensated heart failure [J]. Am J Med, 2020,
133(1): 115-122.e2. DOI: 10.1016/j.amjmed.2019.05.047.
[16] 莫兴全.老年冠心病治疗新进展[J].世界最新医学信息文摘,2019,19(2):29-30.
[17] Banks L, Cacoilo J, Carter J, Oh PI.
Age-related improvements in peak cardiorespiratory fitness among coronary heart
disease patients following cardiac rehabilitation [J]. J Clin Med, 2019,
8(3):310. DOI: 10.3390/jcm8030310.
[18] 郭晓芳,陈静静,陈霞.老年患者冠心病治疗的研究进展[J].医学综述,2021,27(11):2189-2193. DOI:10.3969/j.issn.1006-2084.2021.11.020.
[19] 陆峰. 血浆NT-proBNP水平对冠心病患者病变严重程度的预测价值和经皮冠状动脉介入治疗临床莸益的评价[D].南京: 南京医科大学,2016.
[20] 闫小菊,李勇,张羽,等.血清Hcy、NT-proBNP及脂联素与老年冠心病冠状动脉病变的相关性[J].中国老年学杂志,2020,40(4):673-678.
DOI:10.3969/j.issn.1005-9202. 2020.04.001.
[21] 杨艳,张福军,沈松坤,等.采用ROC曲线评价NT-proBNP、cTnⅠ、Hcy、DD、hs-CRP对冠心病的诊断价值[J].检验医学,2018,33(1):15-19.
[22] 欧阳巍立,江宜乐,龚军辉,等.NT-proBNP与急性心肌梗死患者冠脉病变程度的相关性[J].医学信息,2021,34(22):54-56.
[23] Lindholm D, Lindbäck J, Armstrong PW, et
al. Biomarker-based risk model to predict cardiovascular nortality in patients
with stable coronary disease [J]. J Am Coll Cardiol, 2017, 70(7): 813-826. DOI:
10.1016/j.jacc. 2017.06.030.
[24] Tomasdottir M, Held C, Hadziosmanovic N,
et al. Risk markers of incident atrial fibrillation in patients with coronary
heart disease [J]. Am Heart J, 2021, 233: 92-101. DOI:
10.1016/j.ahj.2020.12.016.
[25] Bai J, Han L, Liu H. Combined use of
high-sensitivity ST2 and NT-proBNP for predicting major adverse cardiovascular
events in coronary heart failure [J]. Ann Palliat Med, 2020, 9(4): 1976-1989.
DOI: 10.21037/apm- 20-1046.
[26] 国家心血管病中心.«中国心血管健康与疾病报告2020»正式出版[J].中国心血管杂志,2021,26(3):276.
[27] 中国高血压防治指南修订委员会,高血压联盟(中国,中华医学会心血管病学分会中国医师协会高血压专业委员会,中国医疗保健国际交流促进会高血压分会,等.中国高血压防治指南( 2018年修订版)[J].中国心血管杂志,2019,24(1):24-56. DOI:10.3969/j.issn.1007-5410.2019.01.002.
[28] 熊兴华,章兴智.原发性高血压左室肥厚与血尿酸、N-BNP相关性分析[J].江西医药,2018,53(3):241-242.
DOI:10.3969/j.issn.1006-2238.2018.3.017.
[29] 钟小明,杨利勇,陈琳,等.不同危险分层原发性高血压患者NT-proBNP水平表达及临床意义[J].江西医药,2021,56(1):59-60. DOI:10.3969/j.issn.1006-2238.2021.01.019.
[30] 洪冰,林祥灿.原发性高血压患者血浆NT-proBNP的检测[J].中国老年学杂志,2013,33(2):298-299.
DOI:10.3969/j.issn.1005-9202.2013.02.023.
[31] Kolte D. Understanding the association
between hypertensive disorders of pregnancy and peripartum cardiomyopathy [J].
Eur J Heart Fail, 2017, 19(12):1721-1722. DOI: 10.1002/ejhf.941.
[32] Kolte D, Khera S, Aronow WS, et al.
Temporal trends in incidence and outcomes of peripartum cardiomyopathy in the
United States: a nationwide population-based study [J]. J Am Heart Assoc, 2014,
3(3): e001056. DOI: 10.1161/JAHA.114.001056.
[33] Davis MB, Arany Z, McNamara DM, et al
Peripartum cardiomyopathy: JACC state-of-the-art review [J]. J Am Coll Cardiol,
2020, 75(2):207-221. DOI: 10.1016/j.jacc.2019.11.014.
[34] 邓勇钢,刘念,谢芸芸.妊娠期高血压疾病患者血清NT-proBNP、ET-1、NO水平及其临床意义[J].海南医学,2020,31(5):566-570. DOI:10.3969/j.issn.1003-6350. 2020.05.006.
[35] 胡仲任,张宇,洪淑蓉,等.血清Cys C、NT-proBNP和ET-1水平对妊娠期高血压疾病早期肾损伤的诊断价值[J].中外医学研究,2021,19(27):58-61.DOI:10.14033/j.cnki.cfmr.2021.27.017.
[36] 李根. 血清中NT-proBNP、Ca2+水平与高血压脑出血及病情严重程度相关性分析[D].沈阳: 沈阳医学院,2021.
[37] 娄延霞,薛凌宇,张学彬,等.泰安市区成年健康查体人群慢性肾脏病流行病学调查分析[J].山东医药,2015,(3):69-71.
DOI:10.3969/j.issn.1002-266X.2015.03.027.
[38] 牟严艳,叶中慧,林梅珍,等.糖尿病流行病学研究进展[J].糖尿病新世界,2019,22(4):196-198.
[39] 何瑜媛,王霞,杨威,等.HbA1c与NT-proBNP在慢性心衰合并2型糖尿病患者中的关系分析[J].现代养生(下半月版),2019(10):35-38.
DOI:10.3969/j.issn.1671-0223.2019. 10.033.
[40] 梁国钦,彭俊,魏文琦,等.血清NT-proBNP、PT3X与急性心肌梗死合并糖尿病患者预后的相关性研究[J].中国医学创新,2020,17(14):132-135.
DOI:10.3969/j.issn.1674-4985. 2020.14.033.
|
